[Federal Register Volume 85, Number 119 (Friday, June 19, 2020)]
[Notices]
[Page 37101]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13278]
[[Page 37101]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2020-0046; NIOSH-233-C]
Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in
Healthcare Settings, 2020; Procedures; and Risk Management Information;
Extension of Comment Period
AGENCY: Centers for Disease Control and Prevention, HHS.
ACTION: Extension of comment period.
-----------------------------------------------------------------------
SUMMARY: On May 1, 2020, the National Institute for Occupational Safety
and Health (NIOSH), within the Center for Disease Control and
Prevention (CDC), opened a docket to obtain public input on the
following draft documents: (1) NIOSH Procedures for Developing the
NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures); (2)
NIOSH List of Hazardous Drugs in Healthcare Settings, 2020 (List), and
(3) Managing Hazardous Drug Exposures: Information for Healthcare
Settings. Comments were to be received by June 30, 2020. NIOSH is
extending the comment period to close on July 30, 2020, to allow
stakeholders and other interested parties additional time to respond.
DATES: The comment period for the document published on May 1, 2020 (85
FR 25439), is extended. Comments must be received by July 30, 2020.
ADDRESSES: You may submit written comments, identified by docket
numbers CDC-2020-0046 and NIOSH-233-C, by either of the following two
methods:
Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
Ohio 45226-1998.
Instructions: All information received in response to this notice
must include the agency name and docket number [CDC-2020-0046; NIOSH-
233-C]. All relevant comments received will be posted without change to
http://www.regulations.gov, including any personal information
provided.
FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A.
Taft Laboratories, 1090 Tusculum Avenue, MS-C26, Cincinnati, OH 45226;
phone: (513) 533-8132 (not a toll-free number); email:
[email protected].
SUPPLEMENTARY INFORMATION: NIOSH published a notice and request for
comment in the Federal Register on May 1, 2020 (85 FR 25439) regarding
the development of the NIOSH List of Hazardous Drugs in Healthcare
Settings and related risk management information for healthcare
settings. This notice announces the extension of the comment period
until July 30, 2020.
John J. Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2020-13278 Filed 6-18-20; 8:45 am]
BILLING CODE 4163-18-P